Idenix Pharmaceuticals LLC v. Gilead Pharmasset LLC
1:15-cv-00416
Overview
Parties
Plaintiff
Universite de Montpellier NPE (Individual / Inventor)
Represented By
3 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Idenix Pharmaceuticals LLC Operating Company
Represented By
11 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Gilead Pharmasset LLC Operating Company
Represented By
1 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Centre National de la Recherche Scientifique Operating Company
Represented By
3 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Counter Defendant
Universita Degli Studi di Cagliari Operating Company
Represented By
3 Attorneys ListedAshby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
Idenix Pharmaceuticals LLC v. Gilead Pharmasset LLC
Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7608600
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
Filed: 2003-06-27
Issued: 2009-10-27
|
Active (1.9 yrs remaining)
+1922d PTA
Expires: 2028-09-30
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+1922 days) / Cellect Scrutiny — Over 1922 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
28
Dispositive
21
Granted
3
Denied
0
Pending / Review
12
Motions by Category
Key Dispositive Motions & Rulings